ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/mesothelioma/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Respiratory / Mesothelioma - Advanced/metastatic
6
trial(s) found.
NCT06535607
Advanced
Phase 2
Recruiting
A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors (
eVOLVE-02
)
bispecific PD-L1/CTLA4 antibody
Cervical cancer
Head and neck squamous cell carcinoma
Oesophageal squamous cell carcinoma
Pleural mesothelioma
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06097728
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (
eVOLVE-Meso
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/CTLA4 antibody
platinum-based antineoplastic agent
Mesothelioma
Pleural mesothelioma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04665206
Advanced
Phase 1 / Phase 2
Recruiting
Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors (
VT3989-001
)
TEAD palmitoylation inhibitor
Mesothelioma
Non-small cell lung cancer
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
ACTRN12624000268549
Advanced
Phase 1
Not yet recruiting
LEPO
: A phase 1 study of Leptospermum petersonii extract for patients with mesothelioma
Mesothelioma
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Not yet recruiting (1)
Recruitment Country and State
VIC (4)
WA (3)
NSW (3)
QLD (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (3)
Phase 2 (1)
Phase 3 (1)
Trial Type
Advanced (6)
Cancer Therapy Class
PD-1/PD-L1
67%
CTLA4
50%
PD-1
50%
PD-L1
33%
EGFR
33%
IL-2
17%
YAP-TEAD
17%
Facility
3168 - Clayton - Monash Medical Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2109 - North Ryde - Macquarie University Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
6009 - Nedlands - Linear Clinical Research (1)
2060 - North Sydney - Mater Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
Cancer Type
Cancer
Mesothelioma
Solid tumour
Thoracic cancer
Gastrointestinal cancer
Pleural mesothelioma
Upper gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Cervical cancer
Gastroesophageal cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Oesophageal cancer
Viral-related cancer
Breast adenocarcinoma
Breast cancer
Colorectal cancer
Exocrine pancreatic cancer
Kidney cancer
Lower gastrointestinal cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Triple-negative breast cancer
Urogenital cancer
Oesophageal squamous cell carcinoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Bladder cancer
Clear cell renal cell carcinoma
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
MSI-H/dMMR solid tumour
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Ovarian cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
Skin cancer
Squamous non-small-cell lung cancer
dMMR solid cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy